The seventh batch of national drug collection is planned to be selected 327, with an average price reduction of 48%

In order to implement the decision -making and deployment of the Party Central Committee and the State Council on promoting the procurement of centralized drugs, under the guidance and guidance of relevant departments such as the National Medical Insurance Bureau, the provinces of the country formed the seventh batch of centralized procurement of drugs for drugs. On the day of Nanjing, the results of the selection were generated in Nanjing, Jiangsu, the official selection results will be released after the publicity. The collection of 60 drugs in this collection is successful. The average price reduction of drugs is planned to be selected by 48%. According to the agreed purchase volume, it is expected to save 18.5 billion yuan per year.

Pharmaceutical companies actively participated in the collection, 488 products from 295 companies participated in the bidding, and 327 products of 217 companies were qualified for selection. Among them, 6 of the six international pharmaceutical companies were selected, and 211 domestic pharmaceutical companies were selected as 321 products, and the proportion of bidding companies was 73%. The average variety of drugs is selected by 5.4 companies, and the supply of diversification and stability has been further enhanced.

This episode of drugs involves 31 treatment categories, including common diseases such as hypertension, diabetes, anti -infection, digestive tract diseases, and major diseases such as lung cancer, liver cancer, kidney cancer, and bowel cancer. Get strong. Taking the first -line liver cancer -targeted Yaolunbutoni capsule as an example, each drop from an average of 108 yuan to an average of 18 yuan, and a healing cycle can save 8,100 yuan. For the first time in the field of lowering blood pressure, it was included in the slow -controlled release agent. The price of nifeding horizontal control was 58%reduced, and the price of Matolol's slow -release tablet was 53%. The burden on the medication of patients with hypertension was significantly reduced. Anti -virus drug Osdivir's per tablet decreased from 4.5 yuan to 1 yuan. In addition, Pfizer's Donalin, Japan's Anstelai Mikafen Pure, Emmiro of Spain, Emmoro, and Bryko Xinyi, Italy, 4 original research medicines In the election, the average price was reduced by 67%.

In terms of procurement rules, this collection adheres to the basic principles of "linked and priced, recruiting one" and "national organization, alliance procurement, platform operation" working mechanism, and make further adjustments and optimizations to strengthen supply guarantees. For the first time, the province will be introduced. Each province will have one main company and one for enterprises to ensure stable clinical use.

Since the establishment of the State Medical Insurance Bureau in 2018, 7 batches of national organizational drugs have been carried out, covering a total of 294 kinds of drugs. According to the pre -mining price, the amount involved accounts for 35%of the annual procurement of chemicals and biopharmaceuticals in public medical institutions. The concentrated volume procurement has become an important model for drug procurement of public hospitals. In the next step, the National Medical Insurance Administration will work with relevant departments to guide the implementation of the selection results in various places and middle school companies to ensure that patients across the country use the selected products after the collection of prices in November 2022.

(Source: People's Daily client)

[Edit: Yu Lina]

- END -